High five for WCT's latest acqusition

By Nick Taylor

- Last updated on GMT

Related tags Clinical trial Pharmacology

The splurge of acquisitions by Worldwide Clinical Trials (WCT) is
continuing unabated with the company wrapping up the take over of
MediQuest.

WCT has now made five acquisitions in the past year as it seeks to establish itself at the forefront of the contract research sector.

Through these acquisitions WCT has gained a presence in more than 30 countries, with the latest take over extending its reach in Eastern, Central and Southern Europe.

Dr Neal Cutler, founder of WCT, said: " The acquisitions we have completed to date significantly enhance our contract research organization capabilities and our ability to manage large, global trials, within our primary therapeutic areas of focus.

That in turn positions us well for future growth.

"We have effectively expanded our operations and significantly enhanced our ability to meet the global needs of pharma and biotech companies.

Our presence in Eastern Europe and Russia, two of the most attractive growth regions for clinical trials, helps transform our business into a truly global contract research organization ."

The purchase of Serbia based MediQuest fits in with the selective purchases made over the past 12 months by WCT.

Financial details of this latest acquisition have not been disclosed.

WCT has stated these acquisitions are intended to extend the geographical reach of the company and provide it with complementary skills and facilities.

Over the past 12 months WCT has bought Russian companies Evidence Clinical and Pharmaceutical Research, US-based Clinical Studies Management Group and bioanalytical chemistry specialist CEDRA, and Nottingham Clinical Research, which has its headquarters in the UK.

These acquisitions highlight the ambition of the US-based contract research organisation (CRO), which primarily focuses on research into central nervous system (CNS) and cardiovascular diseases.

In addition to its primary focus on CNS and cardiovascular diseases the company also has experience in treatments for chronic inflammatory disease, metabolism, endocrinology and oncology.

Within these areas of expertise WCT supplies Phase I-IV drug development services to pharmaceutical and biotechnology companies.

The company claims to have increased the quality, safety and speed of drug development by pioneering " revolutionary and innovative " techniques, such as the Bridging and Dynabridge studies.

Related news

Related products

show more

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Overcoming rapid growth challenges with process liquid preparation

Overcoming rapid growth challenges with process liquid preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 01-Nov-2023 | Case Study

A growing contract development manufacturing organization (CDMO) was challenged with the need to quickly expand their process liquid and buffer preparation...

Why should you use clinical trial technology?

Why should you use clinical trial technology?

Content provided by Formedix | 01-Nov-2023 | White Paper

New, innovative clinical trial technology is helping to revolutionize the research landscape. COVID-19 demonstrated that clinical trials can be run much...

Related suppliers

Follow us

Webinars

Headlines